Although altering the broad range of activity by TRIM21 could suggest potential risk of a variety of side effects, TRIM21-targeting therapy may provide a new avenue of SLE treatment, which may offer multiple benefits unattainable by existing therapies. The gene discussed is TRIM21; the disease is systemic lupus erythematosus.